Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 13/20 | 0.64 |
| ▸ | PLG | P00747 | 5/20 | 0.63 |
| ▸ | PLAT | P00750 | 4/20 | 0.63 |
| ▸ | KLK1 | P06870 | 3/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7333152 | 0.83 | PLAU (0.70) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL7342410 | 0.83 | PLAU (0.70) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL7336742 | 0.78 | PLAU (0.76) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL7344350 | 0.78 | PLAU (0.63) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL7336748 | 0.78 | PLAU (0.76) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL7356238 | 0.78 | PLAU (1.00) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL27536270 | 0.77 | PLAU (0.74) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL7344486 | 0.74 | PLAU (0.81) | PLAUPLGPLATKLK1PRMT1 | |
| SCHEMBL27536248 | 0.72 | PLAU (0.67) | PLAUPLGPLATKLK1PRMT1 | |
| Trifluoroacetic Acid SCHEMBL7336137 | 0.72 | PLAU (0.79) | PLAUPLGPLATKLK1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885PLG 10/4885PLAT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.